Related references
Note: Only part of the references are listed.Patterns of Improved Survival in Patients With Multiple Myeloma in the Twenty-First Century: A Population-Based Study
Ingemar Turesson et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13
Donna Reece et al.
BLOOD (2009)
Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma
Christine Chen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG)
E. Kastritis et al.
LEUKEMIA (2009)
Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma
M. A. Dimopoulos et al.
LEUKEMIA (2009)
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review
R. Fonseca et al.
LEUKEMIA (2009)
High-risk myeloma: a gene expression-based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone
Fenghuang Zhan et al.
BLOOD (2008)
Impact of early relapse after auto-SCT for multiple myeloma
S. Kumar et al.
BONE MARROW TRANSPLANTATION (2008)
Improved survival in multiple myeloma and the impact of novel therapies
Shaji K. Kumar et al.
BLOOD (2008)
Extended follow-up of a phase 3 trial in relapsed multiple myeloma:: final time-to-event results of the APEX trial
Paul G. Richardson et al.
BLOOD (2007)
Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma
John Kuruvilla et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2007)
Patterns of survival in multiple myeloma:: A population-based study of patients diagnosed in Sweden from 1973 to 2003
Sigurdur Yngvi Kristinsson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials
S. Jagannath et al.
LEUKEMIA (2007)
International uniform response criteria for multiple myeloma
B. G. M. Durie et al.
LEUKEMIA (2006)
International staging system for multiple myeloma
PR Greipp et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Treatment of relapsed/refractory multiple myeloma with thalidomide-based regimens: Identification of prognostic factors
A Anagnostopoulos et al.
LEUKEMIA & LYMPHOMA (2004)
Clinical and biologic implications of recurrent genomic aberrations in myeloma
R Fonseca et al.
BLOOD (2003)
Share Paper
